| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to medicines in low-income countries
|
Marthe Everard
|
|
2003
|
|
1-2 |
p. 137-149
|
artikel
|
| 2 |
Affordably priced new drugs for poor populations: Approaches for a global solution
|
Elias Mossialos
|
|
2002
|
|
1-2 |
p. 1-29
|
artikel
|
| 3 |
Amodiaquine-induced dystonic reactions: Case reports and implications for policy change in Ghana
|
A.K. Akpalu, Jr.
|
|
2005
|
|
1-2 |
p. 1-4
|
artikel
|
| 4 |
Antidepressants and suicide among young women in Sweden 1999–2013
|
Larsson, Jan
|
|
2017
|
|
1-2 |
p. 101-106
|
artikel
|
| 5 |
Antidepressants and violence: Problems at the interface of medicine and law
|
Healy, David
|
|
2007
|
|
1-2 |
p. 17-33
|
artikel
|
| 6 |
Are there safety concerns for biosimilars?
|
Lekkerkerker, Frits
|
|
2009
|
|
1-2 |
p. 47-52
|
artikel
|
| 7 |
A survey of issues regarding ADR and ADR reporting amongst doctors in Delhi
|
Ashima Bhatia
|
|
2005
|
|
1-2 |
p. 39-46
|
artikel
|
| 8 |
Attainment of target blood pressure and patterns of antihypertensive therapy in type 2 diabetic hypertensive Asian Indians
|
Singh, Nitesh
|
|
2008
|
|
1-2 |
p. 45-50
|
artikel
|
| 9 |
Attitudes to pharmaceutical promotion techniques among healthcare professionals in the Republic of Tatarstan, Russia
|
Burashnikova, Irene S.
|
|
2008
|
|
1-2 |
p. 57-71
|
artikel
|
| 10 |
Atypical antipsychotic agents for the schizophrenia prodrome: Not a clear first choice
|
Kruszewski, Stefan P.
|
|
2008
|
|
1-2 |
p. 37-44
|
artikel
|
| 11 |
Biologicals
|
van Boxtel, Chris J.
|
|
2009
|
|
1-2 |
p. 1-3
|
artikel
|
| 12 |
Biologicals in Japan
|
Hama, Rokuro
|
|
2009
|
|
1-2 |
p. 59-68
|
artikel
|
| 13 |
Biopharmaceuticals in the Russian Federation: A snapshot of policies for registration, reimbursement and use
|
Ziganshina, Lilia E.
|
|
2009
|
|
1-2 |
p. 75-88
|
artikel
|
| 14 |
Biosimilar medicines and safety: New challenges for pharmacovigilance
|
Rägo, Lembit
|
|
2009
|
|
1-2 |
p. 5-11
|
artikel
|
| 15 |
Biosimilars: The French policy
|
Schück, Stéphane
|
|
2009
|
|
1-2 |
p. 41-45
|
artikel
|
| 16 |
Book Review
|
Dukes, Graham
|
|
2008
|
|
1-2 |
p. 107-108
|
artikel
|
| 17 |
Book Review
|
Edwards, I. Ralph
|
|
2007
|
|
1-2 |
p. 109-110
|
artikel
|
| 18 |
British diplomat cleared of drunk flying charges: Paroxetine was involved
|
Herxheimer, Andrew
|
|
2007
|
|
1-2 |
p. 35-40
|
artikel
|
| 19 |
Claim and counterclaim: The treatment of Attention Deficit Hyperactivity Disorder (ADHD) – Preventing or contributing to the development of Substance Use Disorder (SUD)?
|
Kean, Brian
|
|
2007
|
|
1-2 |
p. 65-74
|
artikel
|
| 20 |
Clinical trials and drug promotion: Selective reporting of study 329
|
Jureidini, Jon N.
|
|
2008
|
|
1-2 |
p. 73-81
|
artikel
|
| 21 |
Communicating with patients about harms and risks
|
Andrew Herxheimer
|
|
2005
|
|
1-2 |
p. 23-26
|
artikel
|
| 22 |
Compensation for drug injury: A novel solution for diethylstilbestrol?
|
Dukes, M.N. Graham
|
|
2007
|
|
1-2 |
p. 87-91
|
artikel
|
| 23 |
Conflicts of interest in medical research in Germany and USA: A scrutiny of legal and ethical guidelines for reviewers and investigators
|
Ritlewski, Kristoff M.
|
|
2007
|
|
1-2 |
p. 41-56
|
artikel
|
| 24 |
Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations
|
Shnier, Adrienne
|
|
2017
|
|
1-2 |
p. 1-16
|
artikel
|
| 25 |
Contribution of clinical pharmacology to improve the use of medicines in developing countries
|
Sri Suryawati
|
|
2005
|
|
1-2 |
p. 57-64
|
artikel
|
| 26 |
Counterfeit medicines: An intent to deceive
|
Reggi, Valerio
|
|
2007
|
|
1-2 |
p. 105-108
|
artikel
|
| 27 |
Data needed for developing and monitoring policies
|
Elias Mossialos
|
|
2003
|
|
1-2 |
p. 15-27
|
artikel
|
| 28 |
Drugs and Money
|
|
|
2003
|
|
1-2 |
p. 1-3
|
artikel
|
| 29 |
Dutch Health NGO granted Official Relations with World Health Organisation
|
|
|
2008
|
|
1-2 |
p. 109
|
artikel
|
| 30 |
Editorial
|
van Boxtel, Chris J.
|
|
2007
|
|
1-2 |
p. 1-2
|
artikel
|
| 31 |
Editorial
|
van Boxtel, Chris J.
|
|
2008
|
|
1-2 |
p. 1-3
|
artikel
|
| 32 |
Experiences with budgets
|
Christine Huttin
|
|
2003
|
|
1-2 |
p. 81-84
|
artikel
|
| 33 |
Experiences with generics
|
Kees de Joncheere
|
|
2003
|
|
1-2 |
p. 101-109
|
artikel
|
| 34 |
Experiences with patient charges
|
Flora M. Haaijer-Ruskamp
|
|
2003
|
|
1-2 |
p. 93-96
|
artikel
|
| 35 |
Experiences with pharmacy benefit management programmes in the USA
|
Helene L. Lipton
|
|
2003
|
|
1-2 |
p. 111-118
|
artikel
|
| 36 |
Experiences with professional education
|
Stephen Chapman
|
|
2003
|
|
1-2 |
p. 119-125
|
artikel
|
| 37 |
Experiences with reference pricing
|
Christine Huttin
|
|
2003
|
|
1-2 |
p. 85-91
|
artikel
|
| 38 |
Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships
|
Hama, Rokuro
|
|
2008
|
|
1-2 |
p. 5-36
|
artikel
|
| 39 |
Four decades of European medicines regulation: What have they brought us?
|
John A. Lisman
|
|
2005
|
|
1-2 |
p. 73-79
|
artikel
|
| 40 |
Homicidal ideation causally related to therapeutic medications
|
Marks, Donald H.
|
|
2009
|
|
1-2 |
p. 119
|
artikel
|
| 41 |
How the European Union reviews and approves ‘follow-on biologics’ or biosimilar products
|
Rossignol, Nicolas
|
|
2009
|
|
1-2 |
p. 105-109
|
artikel
|
| 42 |
“If nothing goes wrong, is everything alright?” in reverse
|
van Boxtel, C.J.
|
|
2007
|
|
1-2 |
p. 99-103
|
artikel
|
| 43 |
Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies
|
Danborg, Pia Brandt
|
|
2017
|
|
1-2 |
p. 107-124
|
artikel
|
| 44 |
IMS Health reports global biotech sales grew 12.5 percent in 2007, exceeding $75 billionIMS news releases
|
|
|
2009
|
|
1-2 |
p. 111-113
|
artikel
|
| 45 |
Informed consent by cancer patients in Japanese case law
|
Kiyomi Tomita
|
|
2002
|
|
1-2 |
p. 59-65
|
artikel
|
| 46 |
Intoxication anosognosia: The spellbinding effect of psychiatric drugs
|
Breggin, Peter R.
|
|
2007
|
|
1-2 |
p. 3-15
|
artikel
|
| 47 |
Legal issues in dementia
|
Kapp, Marshall B.
|
|
2008
|
|
1-2 |
p. 91-103
|
artikel
|
| 48 |
Making use of economic evaluation
|
David McDaid
|
|
2003
|
|
1-2 |
p. 67-74
|
artikel
|
| 49 |
Managing the aftermath of iatrogenic injury
|
Charles Vincent
|
|
2005
|
|
1-2 |
p. 5-11
|
artikel
|
| 50 |
Measures relating to use of drug subsidy lists and to regulation
|
A.S. Mitchell
|
|
2003
|
|
1-2 |
p. 77-79
|
artikel
|
| 51 |
Meeting highlights from the Committee for Medicinal Products for Human Use, 18–21 February 2008
|
|
|
2008
|
|
1-2 |
p. 111
|
artikel
|
| 52 |
Methods for monitoring and evaluating processes and outcomes
|
Monique F. Mrazek
|
|
2003
|
|
1-2 |
p. 55-66
|
artikel
|
| 53 |
Monitoring the quality of primary care: Use of hospital-based audit studies
|
Phil Hider
|
|
2005
|
|
1-2 |
p. 81-89
|
artikel
|
| 54 |
Off-label use of medicines: The need for good practice guidelines
|
Dooms, Marc
|
|
2017
|
|
1-2 |
p. 17-23
|
artikel
|
| 55 |
Opinions of Maltese doctors and pharmacists on medication errors
|
Tanti, Amy
|
|
2017
|
|
1-2 |
p. 81-99
|
artikel
|
| 56 |
Overview of safety monitoring of biologicals in China
|
Chen, Yixin
|
|
2008
|
|
1-2 |
p. 69-74
|
artikel
|
| 57 |
Patient-risk due to negligence by Locum General Practitioners outside of office hours
|
J.J. Visser
|
|
2002
|
|
1-2 |
p. 41-49
|
artikel
|
| 58 |
Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach?
|
Giezen, Thijs J.
|
|
2009
|
|
1-2 |
p. 53-58
|
artikel
|
| 59 |
Policy options for cost containment of pharmaceuticals
|
Ad H. Rietveld
|
|
2003
|
|
1-2 |
p. 29-54
|
artikel
|
| 60 |
Preliminary safety assessment of sulphadoxine-pyrimethamine during intermittent presumptive treatment of pregnant women in a region with high prevalence of G6PD deficiency
|
A.N.O. Dodoo
|
|
2005
|
|
1-2 |
p. 13-18
|
artikel
|
| 61 |
Prescription audit of NSAIDs and gastroprotective strategy in elderly in primary care
|
Al Khaja, Khalid Ahmed Jassim
|
|
2017
|
|
1-2 |
p. 57-68
|
artikel
|
| 62 |
Priority medicines for the citizens of Europe and the world: A research and development agenda
|
Bart Wijnberg
|
|
2005
|
|
1-2 |
p. 27-37
|
artikel
|
| 63 |
Providing affordable medicines in transitional countries
|
Kees de Joncheere
|
|
2003
|
|
1-2 |
p. 127-135
|
artikel
|
| 64 |
Psychosocial consequences of screening for albuminuria and certain other risk factors
|
Tymstra, Tjeerd
|
|
2002
|
|
1-2 |
p. 51-57
|
artikel
|
| 65 |
Quality and safety considerations for recombinant biological medicines: A regulatory perspective
|
Barnes, Henry J.
|
|
2009
|
|
1-2 |
p. 13-22
|
artikel
|
| 66 |
Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications
|
Priyanka, Poka Siva Sai Lakshmi
|
|
2017
|
|
1-2 |
p. 25-55
|
artikel
|
| 67 |
Regional pharmacovigilance practice in China
|
Yue, Wang
|
|
2008
|
|
1-2 |
p. 51-56
|
artikel
|
| 68 |
Risky procedures: Experiences and views of psychiatrists and views of management of mental health care institutions
|
J. de Bie
|
|
2005
|
|
1-2 |
p. 47-56
|
artikel
|
| 69 |
Sandoz receives European Commission approval for biosimilar filgrastimNovartis Media releases
|
|
|
2009
|
|
1-2 |
p. 117
|
artikel
|
| 70 |
“Scalpel safety”: Modeling the effectiveness of different safety devices' ability to reduce scalpel blade injuries
|
Fuentes, Hector
|
|
2008
|
|
1-2 |
p. 83-89
|
artikel
|
| 71 |
Scope of the problem
|
Kees de Joncheere
|
|
2003
|
|
1-2 |
p. 7-13
|
artikel
|
| 72 |
Switching to non-prescription status
|
Peter R. Noyce
|
|
2003
|
|
1-2 |
p. 97-99
|
artikel
|
| 73 |
Tainted blood in Canada: An extraordinary history
|
Dukes, M.N. Graham
|
|
2009
|
|
1-2 |
p. 89-92
|
artikel
|
| 74 |
The business case for medical informed consent
|
Kapp, Marshall B.
|
|
2007
|
|
1-2 |
p. 57-64
|
artikel
|
| 75 |
The doctor as expert witness in court: Observations and lessons from the Philippines
|
Hartigan-Go, Kenneth Y.
|
|
2007
|
|
1-2 |
p. 93-97
|
artikel
|
| 76 |
The establishment of the Drug Naming Committee to restrict look-alike medication names in Iran: A qualitative study
|
Abolhassani, Nazanin
|
|
2017
|
|
1-2 |
p. 69-79
|
artikel
|
| 77 |
The First Meeting of Hand Hygiene Campaigning Nations: WHO World Alliance for Patient Safety, August 2007
|
|
|
2008
|
|
1-2 |
p. 105-106
|
artikel
|
| 78 |
The global biopharma industry and the rise of Indian drug multinationals: Implications for Australian generics policy
|
Löfgren, Hans
|
|
2009
|
|
1-2 |
p. 31-40
|
artikel
|
| 79 |
The Heparin Story
|
Usdin, Steve
|
|
2009
|
|
1-2 |
p. 93-103
|
artikel
|
| 80 |
The pharmaceutical industry in discredit: Mercury or Aesculapius?
|
L. Offerhaus
|
|
2005
|
|
1-2 |
p. 19-22
|
artikel
|
| 81 |
The role of drug donations on hospital use of antibiotics during the war and postwar period
|
Ranko Škrbić
|
|
2002
|
|
1-2 |
p. 31-40
|
artikel
|
| 82 |
Title Unavailable
|
|
|
2002
|
|
1-2 |
p. 67-70
|
artikel
|
| 83 |
Tort, error and talk: What can we learn from the litigation crisis?
|
Hugman, Bruce
|
|
2007
|
|
1-2 |
p. 75-86
|
artikel
|
| 84 |
UK biotech seeks bail out
|
|
|
2009
|
|
1-2 |
p. 115-116
|
artikel
|
| 85 |
Unfinished business: Clinical Pharmacology and World Health
|
Anthony J. Smith
|
|
2005
|
|
1-2 |
p. 65-71
|
artikel
|
| 86 |
Vaccine policy, regulations and safety in India
|
Gogtay, N.J.
|
|
2009
|
|
1-2 |
p. 23-30
|
artikel
|
| 87 |
WHO News
|
|
|
2005
|
|
1-2 |
p. 91-92
|
artikel
|
Tijdschrift beschrijving